Lisocabtagene Maraleucel
drugOn this page
Also known as BreyanziJCAR-017JCAR017Lisocabtagen maraleucel
Summary
Lisocabtagene Maraleucel (CHEMBL4297236) is a phase-3 clinical-stage gene (ATC L01XL08); indicated across 7 conditions including non-hodgkin lymphoma and diffuse large b-cell lymphoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Gene
- ATC class: L01XL08
- Indications: 7 conditions
- Clinical trials: 21
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297236 |
| Name | Lisocabtagene Maraleucel |
| Type | Gene |
| Max phase | 3 |
| ATC | L01XL08 |
Also known as: Breyanzi, JCAR-017, JCAR017, Lisocabtagen maraleucel, Lisocabtagene maraleucel, LISOCABTAGENE MARALEUCEL
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| non-Hodgkin lymphoma | 3 | MONDO:0018908 | EFO:0005952 |
| diffuse large B-cell lymphoma | 2 | MONDO:0018905 | EFO:0000403 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| B-cell chronic lymphocytic leukemia | 1 | MONDO:0004948 | EFO:0000095 |
| acute lymphoblastic leukemia | 1 | MONDO:0004967 | EFO:0000220 |
| mantle cell lymphoma | 1 | MONDO:0018876 | EFO:1001469 |
| follicular lymphoma | 1 | MONDO:0018906 | MONDO:0018906 |
Clinical trials
Total trials: 21.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 9 |
| Not specified | 5 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 2 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07188558 | PHASE3 | RECRUITING | A Study to Investigate Ronde-cel Versus Investigator’s Choice CD19 CAR T-Cell Therapy |
| NCT03575351 | PHASE3 | COMPLETED | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas |
| NCT04245839 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) |
| NCT05583149 | PHASE2 | ACTIVE_NOT_RECRUITING | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas |
| NCT05633615 | PHASE2 | RECRUITING | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT05672173 | PHASE2 | RECRUITING | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter’s Transformation |
| NCT05873712 | PHASE2 | RECRUITING | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter’s Syndrome |
| NCT07098364 | PHASE1/PHASE2 | RECRUITING | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma |
| NCT07194980 | PHASE2 | RECRUITING | Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| NCT03310619 | PHASE1/PHASE2 | COMPLETED | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies |
| NCT03483103 | PHASE2 | COMPLETED | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) |
| NCT03484702 | PHASE2 | COMPLETED | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma |
| NCT03743246 | PHASE1/PHASE2 | TERMINATED | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) |
| NCT03744676 | PHASE2 | COMPLETED | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) |
| NCT05359211 | PHASE1 | ACTIVE_NOT_RECRUITING | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma |
| NCT05075603 | PHASE1 | COMPLETED | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy |
| NCT06357754 | Not specified | RECRUITING | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy |
| NCT06788639 | Not specified | RECRUITING | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting |
| NCT06788652 | Not specified | RECRUITING | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting |
| NCT06794268 | Not specified | RECRUITING | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting |
| NCT03436771 | Not specified | TERMINATED | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: non-Hodgkin lymphoma